

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 2, 2023

**Consolidated Financial Summary
for the First Nine Months of the Fiscal Year Ending March 31, 2023
(Under Japanese GAAP)**

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to submit the Quarterly Securities Report: February 6, 2023

Scheduled date to commence dividend payments: –

Preparation of supplementary documents to the quarterly financial results: None

Holding of quarterly financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2022 through December 31, 2022)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended								
December 31, 2022	51,729	14.7	8,550	55.6	6,957	24.0	5,980	47.9
December 31, 2021	45,104	11.7	5,495	41.6	5,613	57.6	4,043	9.2

Note: Comprehensive income: For the nine months ended December 31, 2022: 13,040 million yen [501.0%]

For the nine months ended December 31, 2021: 2,169 million yen [(45.8)%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2022	135.31	–
December 31, 2021	89.33	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
December 31, 2022	137,076	65,989	48.0	1,489.11
March 31, 2022	124,282	55,092	44.2	1,236.09

Reference: Equity: As of December 31, 2022: 65,729 million yen

As of March 31, 2022: 54,894 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2022	–	17.00	–	18.00	35.00
Year ending March 31, 2023	–	18.00	–		
Year ending March 31, 2023 (Forecast)				20.00	38.00

Note: Revision of the forecast of dividends most recently announced: Yes

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2023 (April 1, 2022 through March 31, 2023)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	66,000	10.9	7,000	10.0	7,000	17.9	5,600	41.4	126.74

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Changes in significant subsidiaries during the nine months ended December 31, 2022 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: Yes

4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of December 31, 2022: 53,119,190 shares As of March 31, 2022: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of December 31, 2022: 8,978,982 shares As of March 31, 2022: 8,709,322 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the nine months ended December 31, 2022: 44,200,883 shares

For the nine months ended December 31, 2021: 45,266,623 shares

* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.